Abstract:Shuo-Fu Chen, 1, &ast Min Kau, 2, &ast Yu-Chi Wang, 2 Ming-Hong Chen, 3 Fu-I Tung, 4, 5 Mei-Hsiu Chen, 6 Tse-Ying Liu 2 1 Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; 2 Department of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei, Taiwan; 3 Division of Neurosurgery, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan; 4 Department of Orthopedics, Yang-Ming Branch, Taipei City Hospital, Taipei, Taiwan; 5 Department of Health and Welfare, College of City Management, University of Taipei, Taipei, Taiwan; 6 Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan &astThese authors contributed equally to this work Correspondence: Tse-Ying Liu, Department of Biomedical Engineering, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street, Beitou District, Taipei, 112304, Taiwan, Tel +8862 28267923, Email Purpose: Glioblastoma is a highly aggressive brain tumor with universally poor outcomes. Recent progress in immune checkpoint inhibitors has led to increased interest in their application in glioblastoma. Nonetheless, the unique immune milieu in the brain has posed remarkable challenges to the efficacy of immunotherapy. We aimed to leverage the radiation-induced immunogenic cell death to overcome the immunosuppressive network in glioblastoma. Methods: We developed a novel approach using the gold-core silica-shell nanoparticles (Au@SiO 2 NPs) in combination with low-dose radiation to enhance the therapeutic efficacy of the immune checkpoint inhibitor (atezolizumab) in brain tumors. The biocompatibility, immune cell recruitment, and antitumor ability of the combinatorial strategy were determined using in vitro assays and in vivo models. Results: Our approach successfully induced the migration of macrophages towards brain tumors and promoted cancer cell apoptosis. Subcutaneous tumor models demonstrated favorable safety profiles and significantly enhanced anticancer effects. In orthotopic brain tumor models, the multimodal therapy yielded substantial prognostic benefits over any individual modalities, achieving an impressive 40% survival rate. Conclusion: In summary, the combination of Au@SiO 2 NPs and low-dose radiation holds the potential to improve the clinical efficacy of immune checkpoint inhibitors. The synergetic strategy modulates tumor microenvironments and enhances systemic antitumor immunity, paving a novel way for glioblastoma treatment. Keywords: brain cancer, silica, gold, atezolizumab, radiation therapy Glioblastoma, formerly known as glioblastoma multiforme (GBM), is the most aggressive and prevalent brain tumor primarily affecting adults. More than 50% of patients experience mortality within 3 months of diagnosis, and the median survival is only 14–16 months. 1,2 The standard of treatment involves maximal surgical resection followed by radiation and temozolomide. 3–5 However, their infiltrative nature presents challenges in achieving complete eradication. 6 Additionally, the blood-brain barrier hinders the effectiveness of systemic delivery route. 7–9 These difficulties have prompted extensive research to explore innovative treatment strategies. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have emerged as a promising avenue in cancer treatment. 10,11 These agents block inhibitory pathways exploited by cancer cells to evade the immunosurveillance, restoring the immune system to mount a more potent attack against cancer cells. 12,13 While ICIs have shown promise in various cancers, 14–19 they remain limited for brain tumors due to the blood-brain barrier, the low immunogenic characteristics, and the immunosuppressive networks. 20–23 To address these challenges, researchers are actively investigating the combination of different treatment modalities, such as photothermal therapy, sonodynamic therapy, and radiotherapy. 24 These treatments have been suggested to induce cell damage, potentially triggering the release of damage-associated molecular patterns (DAMPs) and tumor-associated antigens. 25,26 These molecules can either function as stress signals to alert the immune system or be recognized by antigen-presenting cells, which are responsible for capturing antigens and presenting them to cytotoxic T cells. 27–29 Recent breakthroughs in nanomaterials -Abstract Truncated-

Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy.

Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Targeted Delivery of Chemo-Sonodynamic Therapy via Brain Targeting, Glutathione-Consumable Polymeric Nanoparticles for Effective Brain Cancer Treatment

Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery

A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma

Biomimetic Nanosensitizer Potentiates Efficient Glioblastoma Gene-Radiotherapy through Synergistic Hypoxia Mitigation and PLK1 Silencing

Radiation-Triggered Selenium-Engineered Mesoporous Silica Nanocapsules for RNAi Therapy in Radiotherapy-Resistant Glioblastoma

LDLR-mediated Peptide-22-conjugated Nanoparticles for Dual-Targeting Therapy of Brain Glioma.

NIMG-48. TLR7/8-AGONIST-LOADED NANOPARTICLES REPROGRAM TUMOR-ASSOCIATED MYELOID CELLS FOR EFFECTIVE IMMUNOTHERAPY OF EXPERIMENTAL GLIOMA AND MRI-BASED TREATMENT MONITORING

Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide Nanoparticles

Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation

Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles

Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment

Targeted Radiolabeled Compounds in Glioma Therapy

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles

Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model

Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model

Targeted Delivery of Nanoparticle-Conveyed Neutrophils to the Glioblastoma Site for Efficient Therapy

Brain Tumor-Targeted Therapy by Systemic Delivery of Sirna with Transferrin Receptor-Mediated Core-Shell Nanoparticles.